We read with great interest the case report 'Radiation myelitis following allogeneic stem cell transplantation and consolidation radiotherapy for non-Hodgkin's lymphoma'. 1 In its conclusion, the authors point out that commonly accepted normal tissue radiation tolerance may have limited applicability following dose intensive transplantation therapy. The same point is made by Chao et al 2 concluding that non-hematologic subclinical chemotherapeutic toxicity can occur in a number of normal tissues including spinal cord, which may lead to a lower cord tolerance. Both case reports are the only ones reported dealing with radiation myelopathies after safe RT doses following high-dose chemotherapy with autologous bone marrow transplantation.
Excessive spinal cord toxicity was reported in 1994 by Watterson et al 3 in a group of 23 cases of myelopathy that occurred in patients who received intensive CNS-directed therapy with systemic chemotherapy, intrathecal chemotherapy, and radiation therapy contributing to toxicity. The exact relationship and contribution of each modality to the development of myelitis, remains unknown.
Radiation myelitis is thought to be a consequence of both unrepaired vascular and neuronal damage after a certain dose level.
We think that several recent publications can help in defining a new point of view regarding such toxicity, which would deal with the extreme plasticity of infused bone marrow stem cells.
After intravascular delivery of genetically marked adult mouse bone marrow into lethally irradiated adult normal hosts, 4 donor-derived cells expressing neuronal phenotypes developed in the central nervous system. These cells were in layers in which the majority of neuronal regeneration has been documented to occur in adult mice.
Mezey et al 5 using an immunodeficient mice model, found that infused bone marrow cells were not detected in the spinal cord or brainstem while bone marrow derived stem cells entered the brain and differentiated into cells that expressed neuronal markers, supporting the idea that mesoderm-derived cells can adopt neural cell fates.
These murine models can be compared with patients treated with bone marrow transplant after a myeloablative procedure, keeping in mind that two populations of neural stem cells have been identified in adult mammals, one in the ependimal cell layer lining the ventricles and one in the subventricular zone, each of which give rise to glial cells and neurons. 6, 7 These cell populations would undoubtedly be damaged by high-dose chemotherapy and/or total body irradiation and infused bone marrow cells would readily try to repair such damage.
The exact proportion of damage and the dynamics of repair by infused and remaining cells are factors that should be studied throughly before making any statement about central nervous system toxicity after bone marrow transplant in relation to non-transplanted individuals.
Maybe treatments aimed at common ancestor cells would be beneficial in myelopathy cases. Growth factors with antiapoptotic and/or regenerative (blood vessel +/− oligodendrocyte) potentials have been shown to modulate radiation myelitis of the cervical spinal cord. 8 Green has postulated the existence of a multipotent stem cell that would give rise to neurons, muscle, blood, and endothelium. 9 All these data suggest that radiation myelopathy after bone marrow transplant is a complex situation in which multiple and evolving cell lines are involved and are not just a simple matter of physical dose (45 Gy, 1.8 Gy/day).
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